Iron chelating strategies in systemic metal overload, neurodegeneration and cancer

Current Medicinal Chemistry

Volumn 21, Issue 33, 2014, Pages 3741-3767

  Gumienna Kontecka, Elzbieta ^a   Pyrkosz Bulska, Monika ^b   Szebesczyk, Agnieszka ^a   Ostrowska, Malgorzata ^a  

^a UNIVERSITY OF WROC AW   (Poland)

^b UNIVERSITY OF SILESIA   (Poland)

Author keywords

Cancer; Chelating agents; Iron; Iron overload; Neurodegenerative diseases

Indexed keywords

8 QUINOLINOL DERIVATIVE; ANTINEOPLASTIC AGENT; AROYLHYDRAZONE DERIVATIVE; CLIOQUINOL; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; IRON CHELATING AGENT; O TRENSOX; POLYPHENOL; PYRIDOXAL ISONICOTINOYLHYDRAZONE; SILIBININ; SILICRISTIN; SILIDIANIN; TACHPYRIDINE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; METAL;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BRAIN LEVEL; CANCER CELL; CHELATION THERAPY; DEGENERATIVE DISEASE; DRUG MECHANISM; DRUG STRUCTURE; HOMEOSTASIS; HUMAN; IRON OVERLOAD; IRON TRANSPORT; MONOTHERAPY; NEOPLASM; NERVE DEGENERATION; PARKINSON DISEASE; PATHOLOGY; REVIEW; STOICHIOMETRY; TRANSCRIPTION INITIATION; ANIMAL; METABOLISM; RAT;

ANIMALS; HUMANS; IRON CHELATING AGENTS; METALS; NEOPLASMS; NEURODEGENERATIVE DISEASES; RATS;

EID: 84918496118     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140706143402     Document Type: Review

References (284)

1. nd ed.; Wiley: Chichester; New York, 2001.
2. Faa, G.; Crisponi, G., Iron chelating agents in clinical practice. Coord. Chem. Rev., 1999, 184, 291-310.
3. Aouad, F.; Florence, A.; Zhang, Y.; Collins, F.; Henry, C.; Ward, R. J.; Crichton, R. R. Evaluation of new iron chelators and their therapeutic potential. Inorg. Chim. Acta, 2002, 339, 470-480.
4. Santos, M. A.; Marques, S. M.; Chaves, S. Hydroxypyridinones as "privileged" chelating structures for the design of medicinal drugs. Coord. Chem. Rev., 2012, 256(1-2), 240-259.
5. Weinreb, O.; Mandel, S.; Youdim, M. B. H.; Amit, T. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. Free Radical Biol. Med., 2013, 62, 52-64.
6. Rivera-Mancia, S.; Perez-Neri, I.; Rios, C.; Tristan-Lopez, L.; Rivera-Espinosa, L.; Montes, S. The transition metals copper and iron in neurodegenerative diseases. Chem. Biol. Interact., 2010, 186(2), 184-199.
7. Kaur, D.; Andersen, J. Does cellular iron dysregulation play a causative role in Parkinson's disease? Ageing Res. Rev., 2004, 3(3), 327-343.
8. Crisponi, G.; Remelli, M. Iron chelating agents for the treatment of iron overload. Coord. Chem. Rev., 2008, 252(10-11), 1225-1240.
9. Ganz, T.; Nemeth, E. Hepcidin and iron homeostasis. Biochim. Biophys. Acta Mol. Cell. Res., 2012, 1823(9), 1434-1443.
10. Crisponi, G.; Nurchi, V. M.; Crespo-Alonso, M.; Toso, L. Chelating agents for metal intoxication. Curr. Med. Chem., 2012, 19(17), 2794-2815.
11. Crichton, R. R.; Dexter, D. T.; Ward, R. J. Metal based neurodegenerative diseases - From molecular mechanisms to therapeutic strategies. Coord. Chem. Rev., 2008, 252(10-11), 1189-1199.
12. Shayeghi, M.; Latunde-Dada, G. O.; Oakhill, J. S.; Laftah, A. H.; Takeuchi, K.; Halliday, N.; Khan, Y.; Warley, A.; McCann, F. E.; Hider, R. C.; Frazer, D. M.; Anderson, G. J.; Vulpe, C. D.; Simpson, R. J.; McKie, A. T. Identification of an intestinal heme transporter. Cell, 2005, 122(5), 789-801.
13. Anderson, G. J.; Darshan, D.; Wilkins, S. J.; Frazer, D. M. Regulation of systemic iron homeostasis: how the body responds to changes in iron demand. Biometals, 2007, 20(3-4), 665-674.
14. Potocki, S.; Rowinska-Zyrek, M.; Witkowska, D.; Pyrkosz, M.; Szebesczyk, A.; Krzywoszynska, K.; Kozlowski, H. Metal transport and homeostasis within the human body: toxicity associated with transport abnormalities. Curr. Med. Chem., 2012, 19(17), 2738-2759.
15. Richardson, D. R.; Kalinowski, D. S.; Lau, S.; Jansson, P. J.; Lovejoy, D. B. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim. Biophys. Acta Gen. Subjects, 2009, 1790(7), 702-717.
16. Ke, Y.; Qian, Z. M. Brain iron metabolism: Neurobiology and neurochemistry. Prog. Neurobiol., 2007, 83(3), 149-173.
17. Whitnall, M.; Richardson, D.R. Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin. Pediatr. Neurol., 2006, 13(3), 186-197.
18. Kozlowski, H.; Janicka-Klos, A.; Brasun, J.; Gaggelli, E.; Valensin, D.; Valensin, G. Copper, iron, and zinc ions homeostasis and their role in neurodegenerative disorders (metal uptake, transport, distribution and regulation). Coord. Chem. Rev., 2009, 253(21-22), 2665-2685.
19. Rouault, T. A.; Cooperman, S. Brain iron metabolism. Semin. Pediatr. Neurol., 2006, 13(3), 142-148.
20. Mast, A. E.; Schlumpf, K. S.; Wright, D. J.; Johnson, B.; Glynn, S. A.; Busch, M. P.; Olbina, G.; Westerman, M.; Nemeth, E.; Ganz, T. Hepcidin level predicts hemoglobin concentration in individuals undergoing repeated phlebotomy. Haematologica, 2013, 98(8), 1324-30.
21. Nemeth, E.; Tuttle, M. S.; Powelson, J.; Vaughn, M. B.; Donovan, A.; Ward, D. M.; Ganz, T.; Kaplan, J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science, 2004, 306(5704), 2090-2093.
22. Crichton, R. R.; Dexter, D. T.; Ward, R.J. Brain iron metabolism and its perturbation in neurological diseases. J. Neural. Transm., 2011, 118(3), 301-314.
23. Thompson, K. J.; Shoham, S.; Connor, J. R. Iron and neurodegenerative disorders. Brain Res. Bull., 2001, 55(2), 155-164.
24. Burdo, J. R.; Menzies, S. L.; Simpson, I. A.; Garrick, L. M.; Garrick, M. D.; Dolan, K. G.; Haile, D. J.; Beard, J. L.; Connor, J. R. Distribution of divalent metal transporter 1 and metal transport protein 1 in the normal and Belgrade rat. J. Neurosci. Res., 2001, 66(6), 1198-1207.
25. Wu, L. J. C.; Leenders, A. G. M.; Cooperman, S.; Meyron-Holtz, E.; Smith, S.; Land, W.; Tsai, R. Y. L.; Berger, U. V.; Sheng, Z. H.; Rouault, T. A. Expression of the iron transporter ferroportin in synaptic vesicles and the blood-brain barrier. Brain Res., 2004, 1001(1-2), 108-117.
26. Zechel, S.; Huber-Wittmer, K.; von Bohlen und Halbach, O. Distribution of the iron-regulating protein hepcidin in the murine central nervous system. J. Neurosci. Res., 2006, 84(4), 790-800.
27. Lovejoy, D. B.; Richardson, D. R. Iron chelators as anti-neoplastic agents: Current developments and promise of the PIH class of chelators. Curr. Med. Chem., 2003, 10(12), 1035-1049.
28. Yu, Y.; Wong, J.; Lovejoy, D. B.; Kalinowski, D. S.; Richardson, D. R. Chelators at the cancer coalface: Desferrioxamine to triapine and beyond. Clin. Cancer Res., 2006, 12(23), 6876-6883.
29. Kolberg, M.; Strand, K. R.; Graff, P.; Andersson, K. K. Structure, function, and mechanism of ribonucleotide reductases. Biochim. Biophys. Acta Proteins Proteom., 2004, 1699(1-2), 1-34.
30. Gao, J.; Richardson, D. R., The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression. Blood, 2001, 98(3), 842-850.
31. Dhillon, A. S.; Hagan, S.; Rath, O.; Kolch, W. MAP kinase signalling pathways in cancer. Oncogene, 2007, 26(22), 3279-3290.
32. Yu, Y.; Kovacevic, Z.; Richardson, D. R. Tuning cell cycle regulation with an iron key. Cell Cycle, 2007, 6(16), 1982-1994.
33. Wilkinson, M. G.; Millar, J. B. A. Control of the eukaryotic cell cycle by MAP kinase signaling pathways. FASEB J., 2000, 14(14), 2147-2157.
34. Bae, D. H.; Jansson, P. J.; Huang, M. L.; Kovacevic, Z.; Kalinowski, D.; Lee, C. S.; Sahni, S.; Richardson, D. R. The role of NDRG1 in the pathology and potential treatment of human cancers. J. Clin. Pathol., 2013, 66(11), 911-917.
35. Kovacevic, Z.; Chikhani, S.; Lovejoy, D. B.; Richardson, D. R. Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: A new strategy for the treatment of pancreatic cancer. Mol. Pharmacol., 2011, 80(4), 598-609.
36. Le, N. T. V.; Richardson, D. R. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood, 2004, 104(9), 2967-2975.
37. Noulsri, E.; Richardson, D. R.; Lerdwana, S.; Fucharoen, S.; Yamagishi, T.; Kalinowski, D. S.; Pattanapanyasat, K. Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells. Am. J. Hematol., 2009, 84(3), 170-176.
38. Valko, M.; Rhodes, C. J.; Moncol, J.; Izakovic, M.; Mazur, M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact., 2006, 160(1), 1-40.
39. Sochaski, M. A.; Bartfay, W. J.; Thorpe, S. R.; Baynes, J. W.; Bartfay, E.; Lehotay, D. C.; Liu, P. P. Lipid peroxidation and protein modificationin a mouse model of chronic iron overload. Metabolism, 2002, 51(5), 645-651.
40. Yu, Y.; Kalinowski, D. S.; Kovacevic, Z.; Siafakas, A. R.; Jansson, P. J.; Stefani, C.; Lovejoy, D. B.; Sharpe, P. C.; Bernhardt, P. V.; Richardson, D. R. Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J. Med. Chem., 2009, 52(17), 5271-5294.
41. Merlot, A. M.; Kalinowski, D. S.; Richardson, D. R. Novel chelators for cancer treatment: Where are we now? Antioxid. Redox Sign., 2013, 18(8), 973-1006.
42. Kalinowski, D. S.; Richardson, D. R. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev., 2005, 57(4), 547-583.
43. Kwok, J. C.; Richardson, D. R. The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit. Rev. Oncol. Hemat., 2002, 42(1), 65-78.
44. European Association For The Study Of The Liver. EASL clinical practice guidelines for HFE hemochromatosis. J. Hepatol., 2010, 53(1), 3-22.
45. Hanson, E. H.; Imperatore, G.; Burke, W. HFE gene and hereditary hemochromatosis: A HuGE review. Am. J. Epidemiol., 2001, 154(3), 193-206.
46. Flaten, T. P.; Aaseth, J.; Andersen, O.; Kontoghiorghes, G. J. Iron mobilization using chelation and phlebotomy. J. Trace Elem. Med. Bio., 2012, 26(2-3), 127-130.
47. Hentze, M. W.; Muckenthaler, M. U.; Galy, B.; Camaschella, C. Two to tango: regulation of mammalian iron metabolism. Cell, 2010, 142(1), 24-38.
48. Silva, A. M. N.; Hider, R. C. Influence of non-enzymatic post-translation modifications on the ability of human serum albumin to bind iron Implications for non-transferrin-bound iron speciation. Biochim. Biophys. Acta Proteins Proteom., 2009, 1794(10), 1449-1458.
49. Hider, R. C.; Silva, A. M.; Podinovskaia, M.; Ma, Y. Monitoring the efficiency of iron chelation therapy: the potential of nontransferrin-bound iron. Ann. N. Y. Acad. Sci., 2010, 1202, 94-9.
50. Zhou, T.; Ma, Y. M.; Kong, X. L.; Hider, R. C. Design of iron chelators with therapeutic application. Dalton Trans., 2012, 41(21), 6371-6389.
51. Askari, F.; Innis, D.; Dick, R. B.; Hou, G. Q.; Marrero, J.; Greenson, J.; Brewer, G. J. Treatment of primary biliary cirrhosis with tetrathiomolybdate: results of a double-blind trial. Transl. Res., 2010, 155(3), 123-130.
52. Niederau, C.; Fischer, R.; Purschel, A.; Stremmel, W.; Haussinger, D.; Strohmeyer, G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology, 1996, 110(4), 1107-1119.
53. Rund, D.; Rachmilewitz, E. Medical progress: beta-thalassemia. New Engl. J. Med., 2005, 353(11), 1135-1146.
54. Forni, G. L.; Podesta, M.; Musso, M.; Piaggio, G.; Musallam, K. M.; Balocco, M.; Pozzi, S.; Rosa, A.; Frassoni, F. Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with beta-thalassemia major. Haematologica, 2013, 98(4), 555-559.
55. Galanello, R.; Agus, A.; Campus, S.; Danjou, F.; Giardina, P. J.; Grady, R. W. Combined iron chelation therapy. Ann. N. Y. Acad. Sci. USA, 2010, 1202, 79-86.
56. Taher, A. T.; Viprakasit, V.; Musallam, K. M.; Cappellini, M. D. Treating iron overload in patients with non-transfusion-dependent thalassemia. Am. J. Hematol., 2013, 88(5), 409-415.
57. Michlitsch, J.; Azimi, M.; Hoppe, C.; Walters, M. C.; Lubin, B.; Lorey, F.; Vichinsky, E. Newborn screening for hemoglobinopathies in California. Pediatr. Blood Cancer, 2009, 52(4), 486-490.
58. Pippard, M. J.; Warner, G. T.; Callender, S. T.; Weatherall, D. J. Iron-absorption and loading in beta-thalassemia intermedia. Lancet, 1979, 2(8147), 819-821.
59. Cohen, A. R.; Glimm, E.; Porter, J. B. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood, 2008, 111(2), 583-587.
60. Musallam, K. M.; Cappellini, M. D.; Wood, J. C.; Motta, I.; Graziadei, G.; Tamim, H.; Taher, A. T. Elevated liver iron concentration is a marker of increased morbidity in patients with beta thalassemia intermedia. Haematol. Hematol. J., 2011, 96(11), 1605-1612.
61. Kozlowski, H.; Luczkowski, M.; Remelli, M.; Valensin, D. Copper, zinc and iron in neurodegenerative diseases (Alzheimer's, Parkinson's and prion diseases). Coord. Chem. Rev., 2012, 256(19-20), 2129-2141.
62. Stankiewicz, J.; Panter, S. S.; Neema, M.; Arora, A.; Batt, C. E.; Bakshi, R. Iron in chronic brain disorders: Imaging and neurotherapeutic implications. Neurotherapeutics, 2007, 4(3), 371-386.
63. Wilson, R. B. Iron dysregulation in Friedreich ataxia. Semin. Pediatr. Neurol., 2006, 13(3), 166-175.
64. Scott, L. E.; Orvig, C. Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease. Chem. Rev., 2009, 109(10), 4885-4910.
65. Morita, A.; Abdireyim, D.; Kimura, M.; Itokawa, Y. The effect of aging on the mineral status of female SAMP1 and SAMR1. Biol. Trace. Elem. Res., 2001, 80(1), 53-65.
66. Takahashi, S.; Takahashi, I.; Sato, H.; Kubota, Y.; Yoshida, S.; Muramatsu, Y. Age-related changes in the concentrations of major and trace elements in the brain of rats and mice. Biol. Trace Elem. Res., 2001, 80(2), 145-158.
67. Rodriguez-Rodriguez, C.; Telpoukhovskaia, M.; Orvig, C. The art of building multifunctional metal-binding agents from basic molecular scaffolds for the potential application in neurodegenerative diseases. Coord. Chem. Rev., 2012, 256(19-20), 2308-2332.
68. Ke, Y.; Qian, Z. M. Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol., 2003, 2(4), 246-253.
69. Bolognin, S.; Messori, L.; Zatta, P. Metal ion physiopathology in neurodegenerative disorders. Neuromol. Med., 2009, 11(4), 223-238.
70. Kell, D. B. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch. Toxicol., 2010, 84(11), 825-889.
71. Sian-Hulsmann, J.; Mandel, S.; Youdim, M. B. H.; Riederer, P. The relevance of iron in the pathogenesis of Parkinson's disease. J. Neurochem., 2011, 118(6), 939-957.
72. Venda, L. L.; Cragg, S. J.; Buchman, V. L.; Wade-Martins, R. alpha-Synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci., 2010, 33(12), 559-568.
73. Ward, R. J.; Dexter, D. T.; Crichton, R. R. Chelating agents for neurodegenerative diseases. Curr. Med. Chem., 2012, 19(17), 2760-2772.
74. Faucheux, B. A.; Martin, M. E.; Beaumont, C.; Hauw, J. J.; Agid, Y.; Hirsch, E. C. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J. Neurochem., 2003, 86(5), 1142-1148.
75. Lopiano, L.; Chiesa, M.; Digilio, G.; Giraudo, S.; Bergamasco, B.; Torre, E.; Fasano, M. Q-band EPR investigations of neuromelanin in control and Parkinson's disease patients. Biochim. Biophys. Acta Mol. Basis Dis., 2000, 1500(3), 306-312.
76. Double, K. L.; Ben-Shachar, D.; Youdim, M. B. H.; Zecca, L.; Riederer, P.; Gerlach, M. Influence of neuromelanin on oxidative pathways within the human substantia nigra. Neurotoxicol. Teratol., 2002, 24(5), 621-628.
77. Sparaco, M.; Gaeta, L. M.; Santorelli, F. M.; Passarelli, C.; Tozzi, G.; Bertini, E.; Simonati, A.; Scaravilli, F.; Taroni, F.; Duyckaerts, C.; Feleppa, M.; Piemonte, F. Friedreich's ataxia: Oxidative stress and cytoskeletal abnormalities. J. Neurol. Sci., 2009, 287(1-2), 111-118.
78. Marmolino, D. Friedreich's ataxia: Past, present and future. Brain Res. Rev., 2011, 67(1-2), 311-330.
79. Duce, J. A.; Bush, A. I. Biological metals and Alzheimer's disease: Implications for therapeutics and diagnostics. Prog. Neurobiol., 2010, 92(1), 1-18.
80. Bush, A. I. The metallobiology of Alzheimer's disease. Trends. Neurosci., 2003, 26(4), 207-214.
81. Connor, J. R.; Snyder, B. S.; Beard, J. L.; Fine, R. E.; Mufson, E. J. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimers-disease. J. Neurosci. Res., 1992, 31(2), 327-335.
82. Smith, D. G.; Cappai, R.; Barnham, K. J. The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim. Biophys. Acta Biomembranes, 2007, 1768(8), 1976-1990.
83. Dumas, E. M.; Versluis, M. J.; van den Bogaard, S. J. A.; van Osch, M. J. P.; Hart, E. P.; van Roon-Mom, W. M. C.; van Buchem, M. A.; Webb, A. G.; van der Grond, J.; Roos, R. A. C. Elevated brain iron is independent from atrophy in Huntington's Disease. Neuroimage, 2012, 61(3), 558-564.
84. Singh, A.; Qing, L. T.; Kong, Q. Z.; Singh, N. Change in the characteristics of ferritin induces iron imbalance in prion disease affected brains. Neurobiol. Dis., 2012, 45(3), 930-938.
85. Jackson, G. E. Handbook of metal-ligand interactions in biological fluids: bioinorganic medicine. Marcel Dekker: New York, 1995; Vol. 2.
86. Jones, M. M. The design of therapeutic chelating-agents. J. Coord. Chem., 1991, 23(1-4), 187-200.
87. Perez, L. R.; Franz, K. J. Minding metals: Tailoring multifunctional chelating agents for neurodegenerative disease. Dalton Trans., 2010, 39(9), 2177-2187.
88. Tilbrook, G. S.; Hider, R. C. Iron chelators for clinical use. Met. Ions Biol. Syst., 1998, 35, 691-730.
89. Hider, R. C.; Roy, S.; Ma, Y. M.; Le Kong, X.; Preston, J. The potential application of iron chelators for the treatment of neurodegenerative diseases. Metallomics, 2011, 3(3), 239-249.
90. Bolognesi, M. L.; Bartolini, M.; Tarozzi, A.; Morroni, F.; Lizzi, F.; Milelli, A.; Minarini, A.; Rosini, M.; Hrelia, P.; Andrisano, V.; Melchiorre, C. Multitargeted drugs discovery: Balancing anti-amyloid and anticholinesterase capacity in a single chemical entity. Bioorg. Med. Chem. Lett., 2011, 21(9), 2655-2658.
91. Braymer, J. J.; Choi, J. S.; DeToma, A. S.; Wang, C.; Nam, K.; Kampf, J. W.; Ramamoorthy, A.; Lim, M. H. Development of bifunctional stilbene derivatives for targeting and modulating metal-amyloid-beta species. Inorg. Chem., 2011, 50(21), 10724-10734.
92. Schugar, H.; Green, D. E.; Bowen, M. L.; Scott, L. E.; Storr, T.; Bohmerle, K.; Thomas, F.; Allen, D. D.; Lockman, P. R.; Merkel, M.; Thompson, K. H.; Orvig, C. Combating Alzheimer's disease with multifunctional molecules designed for metal passivation. Angew. Chem. Int. Edit., 2007, 46(10), 1716-1718.
93. Jin, H. X.; Randazzo, J.; Zhang, P.; Kador, P. F. Multifunctional antioxidants for the treatment of age-related diseases. J. Med. Chem., 2010, 53(3), 1117-1127.
94. Mandel, S.; Amit, T.; Bar-Am, O.; Youdim, M. B. H. Iron dysregulation in Alzheimer's disease: Multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog. Neurobiol., 2007, 82(6), 348-360.
95. Andersen, O. Principles and recent developments in chelation treatment of metal intoxication. Chem. Rev., 1999, 99(9), 2683-2710.
96. Hussain, M. A. M.; Green, N.; Flynn, D. M.; Hussein, S.; Hoffbrand, A. V. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload. Lancet, 1976, 2(7998), 1278-1280.
97. Thuret, I. Post-transfusional iron overload in the haemoglobinopathies. Compt. Rend. Biol., 2013, 336(3), 164-172.
98. Lindsey, W. T.; Olin, B. R. Deferasirox for transfusion-related iron overload: A clinical review. Clin. Ther., 2007, 29(10), 2154-2166.
99. Cappellini, M. D.; Gattermann, N.; Viprakasit, V.; Lee, J. W.; Porter, J. B.; El-Beshlawy, A.; Kattamis, A.; Seymour, J. F.; Li, C. K.; Habr, D.; Domokos, G.; Hmissi, A.; Elalfy, M. S. Transfusion history, iron chelation practices and status of iron overload across various transfusion-dependent anemias: data from the large-scale, prospective, 1-year EPIC trial. Blood, 2008, 112(11), 1321-1322.
100. Porter, J. B. Optimizing iron chelation strategies in beta-thalassaemia major. Blood Rev., 2009, 23 Suppl. 1, S3-S7.
101. Evans, P.; Kayyali, R.; Hider, R. C.; Eccleston, J.; Porter, J. B. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. Transl. Res., 2010, 156(2), 55-67.
102. Taher, A. T.; Porter, J.; Viprakasit, V.; Kattamis, A.; Chuncharunee, S.; Sutcharitchan, P.; Siritanaratkul, N.; Galanello, R.; Karakas, Z.; Lawniczek, T.; Ros, J.; Zhang, Y. Y.; Habr, D.; Cappellini, M. D. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood, 2012, 120(5), 970-977.
103. Messa, E.; Carturan, S.; Maffe, C.; Pautasso, M.; Bracco, E.; Roetto, A.; Messa, F.; Arruga, F.; Defilippi, I.; Rosso, V.; Zanone, C.; Rotolo, A.; Greco, E.; Pellegrino, R. M.; Alberti, D.; Saglio, G.; Cilloni, D. Deferasirox is a powerful NF-kappa B inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematol. Hematol. J., 2010, 95(8), 1308-1316.
104. Rienhoff, H. Y.; Viprakasit, V.; Tay, L.; Harmatz, P.; Vichinsky, E.; Chirnomas, D.; Kwiatkowski, J. L.; Tapper, A.; Kramer, W.; Porter, J. B.; Neufeld, E. J. A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematol. Hematol. J., 2011, 96(4), 521-525.
105. Neufeld, E. J.; Galanello, R.; Viprakasit, V.; Aydinok, Y.; Piga, A.; Harmatz, P.; Forni, G. L.; Shah, F. T.; Grace, R. F.; Porter, J. B.; Wood, J. C.; Peppe, J.; Jones, A.; Rienhoff, H. Y. Aphase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood, 2012, 119(14), 3263-3268.
106. Evers, A.; Hancock, R. D.; Martell, A. E.; Motekaitis, R. J. Metal-ion recognition in ligands with negatively charged oxygen donor groups - complexation of Fe(III), Ga(III), In(III), Al(III), and other highly charged metal-ions. Inorg. Chem., 1989, 28(11), 2189-2195.
107. Serratrice, G.; Boukhalfa, H.; Beguin, C.; Baret, P.; Caris, C.; Pierre, J. L. O-TRENSOX, a new tripodal iron chelator based on 8-hydroxyquinoline subunits: Thermodynamic and kinetic studies. Inorg. Chem., 1997, 36(18), 3898-3910.
108. Bernabe-Pineda, M.; Ramirez-Silva, M. T.; Romero-Romo, M. A.; Gonzalez-Vergara, E.; Rojas-Hernandez, A. Spectrophotometric and electrochemical determination of the formation constants of the complexes Curcumin-Fe(Ill)-water and Curcumin-Fe(II)-water. Spectrochim. Acta Part A, 2004, 60(5), 1105-1113.
109. Steinhauser, S.; Heinz, U.; Bartholoma, M.; Weyhermuller, T.; Nick, H.; Hegetschweiler, K. Complex formation of ICL670 and related ligands with Fe-III and Fe-II. Eur. J. Inorg. Chem., 2004, 21, 4177-4192.
110. Vitolo, L. M. W.; Hefter, G. T.; Clare, B. W.; Webb, J. Iron chelators of the pyridoxal isonicotinoyl hydrazone class .2. Formation-constants with iron (iii) and iron (ii). Inorg. Chim. Acta, 1990, 170(2), 171-176.
111. Enyedy, E. A.; Primik, M. F.; Kowol, C. R.; Arion, V. B.; Kiss, T.; Keppler, B. K. Interaction of Triapine and related thiosemicarbazones with iron(III)/(II) and gallium(III): a comparative solution equilibrium study. Dalton Trans., 2011, 40(22), 5895-5905.
112. Nurchi, V. M.; Crisponi, G.; Pivetta, T.; Donatoni, M.; Remelli, M. Potentiometric, spectrophotometric and calorimetric study on iron(III) and copper(II) complexes with 1,2-dimethyl-3-hydroxy-4-pyridinone. J. Inorg. Biochem., 2008, 102(4), 684-692.
113. Elhabiri, M.; Carrer, C.; Marmolle, F.; Traboulsi, H. Complexation of iron(III) by catecholate-type polyphenols. Inorg. Chim. Acta, 2007, 360(1), 353-359.
114. Albert, A.; Hampton, A. Analogues of 8-hydroxyquinoline having additional cyclic nitrogen atoms. 2. Further preparations, and some physico-chemical properties. J. Chem. Soc., 1954, 505-513.
115. Pepe, A.; Meloni, A.; Capra, M.; Cianciulli, P.; Prossomariti, L.; Malaventura, C.; Putti, M. C.; Lippi, A.; Romeo, M. A.; Bisconte, M. G.; Filosa, A.; Caruso, V.; Quarta, A.; Pitrolo, L.; Missere, M.; Midiri, M.; Rossi, G.; Positano, V.; Lombardi, M.; Maggio, A. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematol. Hematol. J., 2011, 96(1), 41-47.
116. Pepe, A.; Lombardi, M.; Positano, V.; Cracolici, E.; Capra, M.; Malizia, R.; Prossomariti, L.; Marchi, D.; Midiri, M.; Maggio, A. Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2&z.ast;. Eur. J. Haematol., 2006, 76(3), 183-192.
117. Origa, R.; Bina, P.; Agus, A.; Crobu, G.; Defraia, E.; Dessi, C.; Leoni, G.; Muroni, P. P.; Galanello, R. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematol. Hematol. J., 2005, 90(10), 1309-1314.
118. Lal, A.; Porter, J.; Sweeters, N.; Ng, V.; Evans, P.; Neumayr, L.; Kurio, G.; Harmatz, P.; Vichinsky, E. Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cell. Mol. Dis., 2013, 50(2), 99-104.
119. Farmaki, K.; Tzoumari, I.; Pappa, C. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Blood. Cell. Mol. Dis., 2011, 47(1), 33-40.
120. Moayedi, B.; Gharagozloo, M.; Esmaeil, N.; Maracy, M. R.; Hoorfar, H.; Jalaeikar, M. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in beta-thalassemia major patients receiving desferrioxamine. Eur. J. Haematol., 2013, 90(3), 202-209.
121. Gazak, R.; Walterova, D.; Kren, V. Silybin and silymarin - New and emerging applications in medicine. Curr. Med. Chem., 2007, 14(3), 315-338.
122. Borsari, M.; Gabbi, C.; Ghelfi, F.; Grandi, R.; Saladini, M.; Severi, S.; Borella, F. Silybin, a new iron-chelating agent. J. Inorg. Biochem., 2001, 85(2-3), 123-129.
123. Saller, R.; Meier, R.; Brignoli, R. The use of silymarin in the treatment of liver diseases. Drugs, 2001, 61(14), 2035-2063.
124. Gharagozloo, M.; Moayedi, B.; Zakerinia, M.; Hamidi, M.; Karimi, M.; Maracy, M.; Amirghofran, Z. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial. Fund. Clin. Pharmacol., 2009, 23(3), 359-365.
125. Hutchinson, C.; Bomford, A.; Geissler, C. A. The iron-chelating potential of silybin in patients with hereditary haemochromatosis. Eur. J. Clin. Nutr., 2010, 64(10), 1239-1241.
126. Betarbet, R.; Sherer, T. B.; Greenamyre, J. T. Animal models of Parkinson's disease. Bioessays, 2002, 24(4), 308-318.
127. Monteiro, H. P.; Winterbourn, C. C. 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid-peroxidation. Biochem. Pharmacol., 1989, 38(23), 4177-4182.
128. Lode, H. N.; Bruchelt, G.; Rieth, A. G.; Niethammer, D. Release of iron from ferritin by 6-hydroxydopamine under aerobic and anaerobic conditions. Free Radical Res. Com., 1990, 11(1-3), 153-158.
129. Linert, W.; Herlinger, E.; Jameson, R. F.; Kienzl, E.; Jellinger, K.; Youdim, M. B. H. Dopamine, 6-hydroxydopamine, iron, and dioxygen - Their mutual interactions and possible implication in the development of Parkinson's disease. Biochim. Biophys. Acta Mol. Basis Dis., 1996, 1316(3), 160-168.
130. Borisenko, G. G.; Kagan, V. E.; Hsia, C. J. C.; Schor, N. F. Interaction between 6-hydroxydopamine and transferrin: "Let my iron go". Biochemistry, 2000, 39(12), 3392-3400.
131. Pezzella, A.; dIschia, M.; Napolitano, A.; Misuraca, G.; Prota, G. Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: A possible contributory mechanism for neuronal degeneration in Parkinson's disease. J. Med. Chem., 1997, 40(14), 2211-2216.
132. Bloem, B. R.; Irwin, I.; Buruma, O. J. S.; Haan, J.; Roos, R. A. C.; Tetrud, J. W.; Langston, J. W. The Mptp model - versatile contributions to the treatment of idiopathic Parkinsons-disease. J. Neurol. Sci., 1990, 97(2-3), 273-293.
133. Ben-Shlomo, Y.; Bhatia, K. Using monoamine oxidase type B inhibitors in Parkinson's disease - They are effective and safe, at least when used alone. Brit. Med. J., 2004, 329(7466), 581-582.
134. Przedborski, S.; Jackson-Lewis, V.; Yokoyama, R.; Shibata, T.; Dawson, V. L.; Dawson, T. M. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. U. S. A., 1996, 93(10), 4565-4571.
135. Gao, H. M.; Liu, B.; Zhang, W. Q.; Hong, J. S. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. FASEB J., 2003, 17(11), 1957-1971.
136. Teismann, P.; Schulz, J. B. Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell. Tissue Res., 2004, 318(1), 149-161.
137. Minghetti, L.; Walsh, D. T.; Levi, G.; Perry, V. H. In vivo expression of cyclooxygenase-2 in rat brain following intraparenchymal injection of bacterial endotoxin and inflammatory cytokines. J. Neuropath. Exp. Neur., 1999, 58(11), 1184-1191.
138. Nagatsu, T.; Sawada, M. Inflammatory process in Parkinson's disease: Role for cytokines. Curr. Pharm. Des., 2005, 11(8), 999-1016.
139. Benshachar, D.; Eshel, G.; Finberg, J. P. M.; Youdim, M. B. H. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem., 1991, 56(4), 1441-1444.
140. Lan, J.; Jiang, D. H. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural. Transm., 1997, 104(4-5), 469-481.
141. Jiang, H.; Luan, Z.; Wang, J.; Xie, J. X. Neuroprotective effects of iron chelator Desferal on dopaminergic neurons in the substantia nigra of rats with iron-overload. Neurochem. Int., 2006, 49(6), 605-609.
142. Molina-Holgado, F.; Gaeta, A.; Francis, P. T.; Williams, R. J.; Hider, R. C. Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells. J. Neurochem., 2008, 105(6), 2466-2476.
143. Dexter, D. T.; Statton, S. A.; Whitmore, C.; Freinbichler, W.; Weinberger, P.; Tipton, K. F.; Della Corte, L.; Ward, R. J.; Crichton, R. R. Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. J. Neural. Transm., 2011, 118(2), 223-231.
144. Waldmeier, P. C.; Buchle, A. M.; Steulet, A. F. Inhibition of catechol-O-methyltransferase (Comt) as well as tyrosine and tryptophan-hydroxylase by the orally-active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (L1, Cp20), in rat-brain in-vivo. Biochem. Pharmacol., 1993, 45(12), 2417-2424.
145. Shachar, D. B.; Kahana, N.; Kampel, V.; Warshawsky, A.; Youdim, M. B. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology, 2004, 46(2), 254-263.
146. Hanson, L. R.; Roeytenberg, A.; Martinez, P. M.; Coppes, V. G.; Sweet, D. C.; Rao, R. J.; Marti, D. L.; Hoekman, J. D.; Matthews, R. B.; Frey, W. H.; Panter, S. S. Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J. Pharmacol. Exp. Ther., 2009, 330(3), 679-686.
147. Zhang, X.; Xie, W. J.; Qu, S.; Pan, T. H.; Wang, X. T.; Le, W. D. Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. Biochem. Biophys. Res. Commun., 2005, 333(2), 544-549.
148. Bareggi, S. R.; Cornelli, U. Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders. Cns. Neurosci. Ther., 2012, 18(1), 41-46.
149. Kaur, D.; Yantiri, F.; Rajagopalan, S.; Kumar, J.; Mo, J. O.; Boonplueang, R.; Viswanath, V.; Jacobs, R.; Yang, L.; Beal, M. F.; DiMonte, D.; Volitaskis, I.; Ellerby, L.; Cherny, R. A.; Bush, A. I.; Andersen, J. K. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: A novel therapy for Parkinson's disease. Neuron, 2003, 37(6), 899-909.
150. Goldstein, L. E.; Leopold, M. C.; Huang, X. D.; Atwood, C. S.; Saunders, A. J.; Hartshorn, M.; Lim, J. T.; Faget, K. Y.; Muffat, J. A.; Scarpa, R. C.; Chylack, L. T.; Bowden, E. F.; Tanzi, R. E.; Bush, A. I. 3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction. Biochemistry, 2000, 39(24), 7266-7275.
151. Wilkins, S.; Masters, C. L.; Bush, A. I.; Cherny, R. A.; Finkelstein, D. I. Clioquinol protects against cell death in Parkinson's disease models in vivo and in vitro. In Advances in behavioral biology. IBAGS IX., Groenewegen, Henk, Ed. Springer: New York, 2009; Vol. 58, pp 431-442.
152. George, J. L.; Mok, S.; Moses, D.; Wilkins, S.; Bush, A. I.; Cherny, R. A.; Finkelstein, D. I. Targeting the progression of Parkinson's disease. Curr. Neuropharmacol., 2009, 7(1), 9-36.
153. Tsubaki, T.; Honma, Y.; Hoshi, M. Neurological syndrome associated with clioquinol. Lancet, 1971, 1(7701), 696-697.
154. Oakley, G. P., Jr. The neurotoxicity of the halogenated hydroxyquinolines. A commentary. JAMA, 1973, 225(4), 395-397.
155. Finkelstein, D. I.; George, J. L.; Adlard, P. A.; Masters, C. L.; Hare, D. J.; Doble, P. A.; Gautier, E.; Parsons, J.; Kok, G.; Huggins, P.; Barnham, K. J.; Bush, A. I.; Cherny, R. A. PBT434, a novel 8-hydroxyquinazolinone, preserves nigro-striatal circuitry, improves motor performance and inhibits alpha synuclein accumulation in animal models of Parkinson's disease by modulation of iron homeostasis. Movement Disord., 2013, 28, S369-S369.
156. th International Conference on Alzheimer's and Parkinson's Diseases in Barcelona.)
157. Ben Shachar, D.; Kahana, N.; Kampel, V.; Warshawsky, A.; Youdim, M. B. H. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology, 2004, 46(2), 254-263.
158. Youdim, M. B. H.; Fridkin, M.; Zheng, H. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases. J. Neural. Transm., 2004, 111(10-11), 1455-1471.
159. Zheng, H. L.; Weiner, L. M.; Bar-Am, O.; Epsztejn, S.; Cabantchik, Z. I.; Warshawsky, A.; Youdim, N. B. H.; Fridkin, M. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorgan. Med. Chem., 2005, 13(3), 773-783.
160. Zheng, H.; Gal, S.; Weiner, L. M.; Bar-Am, O.; Warshawsky, A.; Fridkin, M.; Youdim, M. B. H. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem., 2005, 95(1), 68-78.
161. Levites, Y.; Youdim, M. B. H.; Maor, G.; Mandel, S. Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappa B) activation and cell death by tea extracts in neuronal cultures. Biochem. Pharmacol., 2002, 63(1), 21-29.
162. Gal, S.; Zheng, H.; Fridkin, M.; Youdim, M. B. H. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J. Neurochem., 2005, 95(1), 79-88.
163. Gal, S.; Fridkin, M.; Amit, T.; Zheng, H.; Youdim, M. B. H. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease. J. Neural. Transm. Supp., 2006, 70, 447-456.
164. Zhu, W.; Xie, W.; Pan, T.; Xu, P. G.; Fridkin, M.; Zheng, H.; Jankovic, J.; Youdim, M. B. H.; Le, W. D. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J., 2007, 21(14), 3835-3844.
165. Zheng, H.; Blat, D.; Fridkin, M. Novel neuroprotective neurotrophic NAP analogs targeting metal toxicity and oxidative stress: potential candidates for the control of neurodegenerative diseases. J. Neural Transm. Supp., 2006, 71, 163-172.
166. Blat, D.; Weiner, L.; Youdim, M. B. H.; Fridkin, M. A novel iron-chelating derivative of the neuroprotective peptide NAPVSIPQ shows superior antioxidant and antineurodegenerative capabilities. J. Med. Chem., 2008, 51(1), 126-134.
167. Zheng, H. L.; Youdim, M. B. H.; Weiner, L. M.; Fridkin, M. Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons. Biochem. Pharmacol., 2005, 70(11), 1642-1652.
168. Higdon, J. V.; Frei, B. Tea catechins and polyphenols: Health effects, metabolism, and antioxidant functions. Crit. Rev. Food Sci., 2003, 43(1), 89-143.
169. Perron, N. R.; Brumaghim, J. L. A review of the antioxidant mechanisms of polyphenol compounds related to iron binding. Cell. Biochem. Biophys., 2009, 53(2), 75-100.
170. Levites, Y.; Weinreb, O.; Maor, G.; Youdim, M. B. H.; Mandel, S. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J. Neurochem., 2001, 78(5), 1073-1082.
171. Kim, J. S.; Kim, J. M.; O, J. J.; Jeon, B. S. Inhibition of inducible nitric oxide synthase expression and cell death by (-)- epigallocatechin-3-gallate, a green tea catechin, in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J. Clin. Neurosci., 2010, 17(9), 1165-1168.
172. Nie, G. J.; Jin, C. F.; Cao, Y. L.; Shen, S. R.; Zhao, B. L. Distinct effects of tea catechins on 6-hydroxydopamine-induced apoptosis in PC12 cells. Arch. Biochem. Biophys., 2002, 397(1), 84-90.
173. Wang, L. L.; Xu, S. L.; Xu, X. H.; Chan, P. (-)-Epigallocatechin-3-gallate protects SH-SY5Y cells against 6-OHDA-induced cell death through STAT3 activation. J. Alzheimers Dis., 2009, 17(2), 295-304.
174. Anandhan, A.; Tamilselvam, K.; Radhiga, T.; Rao, S.; Essa, M. M.; Manivasagam, T. Theaflavin, a black tea polyphenol, protects nigral dopaminergic neurons against chronic MPTP/probenecid induced Parkinson's disease. Brain. Res., 2012, 1433, 104-113.
175. Anandhan, A.; Janakiraman, U.; Manivasagam, T. Theaflavin ameliorates behavioral deficits, biochemical indices and monoamine transporters expression against subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (Mptp)-induced mouse model of Parkinson's disease. Neuroscience, 2012, 218, 257-267.
176. Ojha, R. P.; Rastogi, M.; Devi, B. P.; Agrawal, A.; Dubey, G. P. Neuroprotective effect of curcuminoids against inflammation-mediated dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. J. Neuroimmune Pharm., 2012, 7(3), 609-618.
177. Zbarsky, V.; Datla, K. P.; Parkar, S.; Rai, D. K.; Aruoma, O. I.; Dexter, D. T. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free Radical Res., 2005, 39(10), 1119-1125.
178. Patel, M. Y.; Panchal, H. V.; Ghribi, O.; Benzeroual, K. E. The neuroprotective effect of fisetin in the MPTP model of Parkinson's disease. J. Parkinson. Dis., 2012, 2(4), 287-302.
179. Lu, K. T.; Ko, M. C.; Chen, B. Y.; Huang, J. C.; Hsieh, C. W.; Lee, M. C.; Chiou, R. Y.; Wung, B. S.; Peng, C. H.; Yang, Y. L. Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. J. Agric. Food Chem., 2008, 56(16), 6910-6913.
180. Chan, D. K.; Woo, J.; Ho, S. C.; Pang, C. P.; Law, L. K.; Ng, P. W.; Hung, W. T.; Kwok, T.; Hui, E.; Orr, K.; Leung, M. F.; Kay, R. Genetic and environmental risk factors for Parkinson's disease in a Chinese population. J. Neurol. Neurosurg. Psychiatr., 1998, 65(5), 781-784.
181. Checkoway, H.; Powers, K.; Smith-Weller, T.; Franklin, G. M.; Longstreth, W. T., Jr.; Swanson, P. D. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am. J. Epidemiol., 2002, 155(8), 732-738.
182. Tan, E. K.; Tan, C.; Fook-Chong, S. M.; Lum, S. Y.; Chai, A.; Chung, H.; Shen, H.; Zhao, Y.; Teoh, M. L.; Yih, Y.; Pavanni, R.; Chandran, V. R.; Wong, M. C. Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. J. Neurol. Sci., 2003, 216(1), 163-167.
183. Tan, L. C.; Koh, W. P.; Yuan, J. M.; Wang, R.; Au, W. L.; Tan, J. H.; Tan, E. K.; Yu, M. C. Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese Health Study. Am. J. Epidemiol., 2008, 167(5), 553-560.
184. Ross, G. W.; Abbott, R. D.; Petrovitch, H.; Morens, D. M.; Grandinetti, A.; Tung, K. H.; Tanner, C. M.; Masaki, K. H.; Blanchette, P. L.; Curb, J. D.; Popper, J. S.; White, L. R. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA, 2000, 283(20), 2674-2679.
185. Nakaso, K.; Ito, S.; Nakashima, K. Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells. Neurosci. Lett., 2008, 432(2), 146-150.
186. Barranco Quintana, J. L.; Allam, M. F.; Del Castillo, A. S.; Navajas, R. F. Parkinson's disease and tea: a quantitative review. J. Am. Coll. Nutr., 2009, 28(1), 1-6.
187. Richardson, D. R.; Mouralian, C.; Ponka, P.; Becker, E. Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron. Biochim. Biophys. Acta, 2001, 1536(2-3), 133-140.
188. Sohn, Y. S.; Breuer, W.; Munnich, A.; Cabantchik, Z. I. Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood, 2008, 111(3), 1690-1699.
189. Breuer, W.; Ermers, M. J.; Pootrakul, P.; Abramov, A.; Hershko, C.; Cabantchik, Z. I. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood, 2001, 97(3), 792-798.
190. Boddaert, N.; Le Quan Sang, K. H.; Rotig, A.; Leroy-Willig, A.; Gallet, S.; Brunelle, F.; Sidi, D.; Thalabard, J. C.; Munnich, A.; Cabantchik, Z. I. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood, 2007, 110(1), 401-408.
191. Kakhlon, O.; Manning, H.; Breuer, W.; Melamed-Book, N.; Lu, C.; Cortopassi, G.; Munnich, A.; Cabantchik, Z. I. Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. Blood, 2008, 112(13), 5219-5227.
192. Goncalves, S.; Paupe, V.; Dassa, E. P.; Rustin, P. Deferiprone targets aconitase: implication for Friedreich's ataxia treatment. BMC Neurol., 2008, 8, 20.
193. Ponka, P.; Borova, J.; Neuwirt, J.; Fuchs, O. Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett., 1979, 97(2), 317-321.
194. Brittenham, G. M. Pyridoxal isonicotinoyl hydrazone. Effective iron chelation after oral administration. Ann. N. Y. Acad. Sci. USA, 1990, 612, 315-326.
195. Richardson, D. R. B., P. V.; Becker, E. M. Iron chelators and uses thereof. World Patent 2001/017530, March 15, 2001.
196. Becker, E.; Richardson, D. R. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs. J. Lab. Clin. Med. 1999, 134(5), 510-521.
197. Wong, C. S.; Kwok, J. C.; Richardson, D. R. PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice. Biochim. Biophys. Acta, 2004, 1739(1), 70-80.
198. Becton, D. L.; Roberts, B. Antileukemic effects of deferoxamine on human myeloid leukemia cell lines. Cancer Res., 1989, 49(17), 4809-4812.
199. Brard, L.; Granai, C. O.; Swamy, N. Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma. Gynecol. Oncol., 2006, 100(1), 116-127.
200. Blatt, J.; Stitely, S. Antineuroblastoma activity of desferoxamine in human cell lines. Cancer Res., 1987, 47(7), 1749-1750.
201. Simonart, T.; Boelaert, J. R.; Mosselmans, R.; Andrei, G.; Noel, J. C.; De Clercq, E.; Snoeck, R. Antiproliferative and apoptotic effects of iron chelators on human cervical carcinoma cells. Gynecol. Oncol., 2002, 85(1), 95-102.
202. Blatt, J.; Taylor, S. R.; Kontoghiorghes, G. J. Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines. Cancer Res., 1989, 49(11), 2925-2927.
203. Brodie, C.; Siriwardana, G.; Lucas, J.; Schleicher, R.; Terada, N.; Szepesi, A.; Gelfand, E.; Seligman, P. Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle. Cancer Res., 1993, 53(17), 3968-3975.
204. Fan, L.; Iyer, J.; Zhu, S.; Frick, K. K.; Wada, R. K.; Eskenazi, A. E.; Berg, P. E.; Ikegaki, N.; Kennett, R. H.; Frantz, C. N. Inhibition of N-myc expression and induction of apoptosis by iron chelation in human neuroblastoma cells. Cancer Res., 2001, 61(3), 1073-1079.
205. Simonart, T.; Degraef, C.; Andrei, G.; Mosselmans, R.; Hermans, P.; Van Vooren, J. P.; Noel, J. C.; Boelaert, J. R.; Snoeck, R.; Heenen, M. Iron chelators inhibit the growth and induce the apoptosis of Kaposi's sarcoma cells and of their putative endothelial precursors. J. Invest. Dermatol., 2000, 115(5), 893-900.
206. Fukuchi, K.; Tomoyasu, S.; Tsuruoka, N.; Gomi, K. Iron deprivation-induced apoptosis in HL-60 cells. FEBS Lett., 1994, 350(1), 139-142.
207. Estrov, Z.; Tawa, A.; Wang, X. H.; Dube, I. D.; Sulh, H.; Cohen, A.; Gelfand, E. W.; Freedman, M. H. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood, 1987, 69(3), 757-761.
208. Donfrancesco, A.; Deb, G.; Dominici, C.; Pileggi, D.; Castello, M. A.; Helson, L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res., 1990, 50(16), 4929-4930.
209. Hann, H. W.; Stahlhut, M. W.; Rubin, R.; Maddrey, W. C. Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer, 1992, 70(8), 2051-2056.
210. Wang, F.; Elliott, R. L.; Head, J. F. Inhibitory effect of deferoxamine mesylate and low iron diet on the 13762NF rat mammary adenocarcinoma. Anticancer Res., 1999, 19(1A), 445-450.
211. Blatt, J. Deferoxamine in children with recurrent neuroblastoma. Anticancer Res., 1994, 14(5B), 2109-2112.
212. Yamasaki, T.; Terai, S.; Sakaida, I. Deferoxamine for advanced hepatocellular carcinoma. N. Engl. J. Med., 2011, 365(6), 576-578.
213. Kemp, J. D.; Cardillo, T.; Stewart, B. C.; Kehrberg, E.; Weiner, G.; Hedlund, B.; Naumann, P. W. Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor. Cancer Res., 1995, 55(17), 3817-3824.
214. Selig, R. A.; White, L.; Gramacho, C.; Sterling-Levis, K.; Fraser, I. W.; Naidoo, D. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts. Cancer Res., 1998, 58(3), 473-478.
215. Olivieri, N. F.; Brittenham, G. M. Iron-chelating therapy and the treatment of thalassemia. Blood, 1997, 89(3), 739-761.
216. Summers, M. R.; Jacobs, A.; Tudway, D.; Perera, P.; Ricketts, C. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Brit. J. Haematol., 1979, 42(4), 547-555.
217. Nick, H.; Wong, A.; Acklin, P.; Faller, B.; Jin, Y.; Lattmann, R.; Sergejew, T.; Hauffe, S.; Thomas, H.; Schnebli, H. P. ICL670A: Preclinical profile. Adv. Exp. Med. Biol., 2002, 509, 185-203.
218. Chantrel-Groussard, K.; Gaboriau, F.; Pasdeloup, N.; Havouis, R.; Nick, H.; Pierre, J. L.; Brissot, P.; Lescoat, G. The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox. Eur. J. Pharmacol., 2006, 541 (3), 129-137.
219. Lescoat, G.; Chantrel-Groussard, K.; Pasdeloup, N.; Nick, H.; Brissot, P.; Gaboriau, F. Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism. Cell Proliferat., 2007, 40(5), 755-767.
220. Ohyashiki, J. H.; Kobayashi, C.; Hamamura, R.; Okabe, S.; Tauchi, T.; Ohyashiki, K. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci., 2009, 100(5), 970-977.
221. Schipper, R. G.; Penning, L. C.; Verhofstad, A. A. J. Involvement of polyamines in apoptosis. Facts and controversies: effectors or protectors? Semin. Cancer Biol., 2000, 10(1), 55-68.
222. Seiler, N.; Raul, F., Polyamines and apoptosis. J. Cell. Mol. Med., 2005, 9(3), 623-642.
223. Fukushima, T.; Kawabata, H.; Nakamura, T.; Iwao, H.; Nakajima, A.; Miki, M.; Sakai, T.; Sawaki, T.; Fujita, Y.; Tanaka, M.; Masaki, Y.; Hirose, Y.; Umehara, H. Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia. Anticancer Res., 2011, 31(5), 1741-1744.
224. Lui, G. Y. L.; Obeidy, P.; Ford, S. J.; Tselepis, C.; Sharp, D. M.; Jansson, P. J.; Kalinowski, D. S.; Kovacevic, Z.; Lovejoy, D. B.; Richardson, D. R. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Mol. Pharmacol., 2013, 83(1), 179-190.
225. West, D. X.; Padhye, S. B.; Sonawane, P. B. Structural and physical correlations in the biological properties of transition-metal heterocyclic thiosemicarbazone and S-alkyldithiocarbazate complexes. Struct. Bond., 1991, 76, 1-50.
226. Sartorelli, A. C.; Booth, B. A. Inhibition of growth of sarcoma 180 ascites cells by combinations of inhibitors of nucleic acid biosynthesis and cupric chelate of kethoxal bis-(thiosemicarbazone). Cancer Res., 1967, 27(9), 1614-&.
227. Shao, J. M.; Zhou, B. S.; Di Bilio, A. J.; Zhu, L. J.; Wang, T. L.; Qi, C.; Shih, J.; Yen, Y. A ferrous-Triapine complex mediates formation of reactive oxygen species chat inactivate human ribonucleotide reductase. Mol. Cancer Ther., 2006, 5(3), 586-592.
228. Yu, Y.; Richardson, D. R. Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1. J. Biol. Chem., 2011, 286(17), 15413-15427.
229. Lobana, T. S.; Sharma, R.; Bawa, G.; Khanna, S. Bonding and structure trends of thiosemicarbazone derivatives of metals-An overview. Coord. Chem. Rev., 2009, 253 (7-8), 977-1055.
230. Richardson, D. R.; Sharpe, P. C.; Lovejoy, D. B.; Senaratne, D.; Kalinowski, D. S.; Islam, M.; Bernhardt, P. V. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J. Med. Chem., 2006, 49(22), 6510-6521.
231. Chen, J. N.; Huang, Y. W.; Liu, G. S.; Afrasiabi, Z.; Sinn, E.; Padhye, S.; Ma, Y. The cytotoxicity and mechanisms of 1,2-naphtoquinone thiosemicarbazone and its metal derivatives against MCF-7 human breast cancer cells. Toxicol. Appl. Pharm., 2004, 197(1), 40-48.
232. Cooper, C. E.; Lynagh, G. R.; Hoyes, K. P.; Hider, R. C.; Cammack, R.; Porter, J. B. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J. Biol. Chem., 1996, 271(34), 20291-20299.
233. Green, D. A.; Antholine, W. E.; Wong, S. J.; Richardson, D. R.; Chitambar, C. R. Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: Effect on the R2 subunit of ribonucleotide reductase. Clin. Cancer Res., 2001, 7 (11), 3574-3579.
234. Yu, Y.; Rahmanto, Y. S.; Hawkins, C. L.; Richardson, D. R. The potent and novel thiosemicarbazone chelators di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2-benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone affect crucial thiol systems required for ribonucleotide reductase activity. Mol. Pharmacol., 2011, 79(6), 921-931.
235. Li, J.; Zheng, L. M.; King, I.; Doyle, T. W.; Chen, S. H. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehydehyde-thiosemicarbazone (3-Amp), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-Ap) and its water-soluble prodrugs. Curr. Med. Chem., 2001, 8(2), 121-133.
236. Wu, C. P.; Shulkla, S.; Calcagno, A. M.; Hall, M. D.; Gottesman, M. M.; Ambudkar, S. V. Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance-linked ABCG2 transporter. Mol. Cancer Ther., 2007, 6(12), 3287-3296.
237. Chaston, T. B.; Lovejoy, D. B.; Watts, R. N.; Richardson, D. R. Examination of the antiproliferative activity of iron chelators: Multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin. Cancer Res., 2003, 9(1), 402-414.
238. Traynor, A. M.; Lee, J. W.; Bayer, G. K.; Tate, J. M.; Thomas, S. P.; Mazurczak, M.; Graham, D. L.; Kolesar, J. M.; Schiller, J. H. A phase II trial of TriapineA (R) (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503. Invest. New Drugs, 2010, 28(1), 91-97.
239. Deconti, R. C.; Sartorel.Ac; Tomchick, R.; Toftness, B. R.; Bertino, J. R.; Agrawal, K. C.; Mead, J. A. R.; Creasey, W. A. Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone. Cancer Res., 1972, 32(7), 1455-&.
240. Creasey, W. A.; Capizzi, R. L.; Agrawal, K. C.; Stinson, K. K.; Sartorel.A.C. Studies of antineoplastic activity and metabolism of alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazones in dogs and mice. Cancer Res., 1972, 32(3), 565-8.
241. Moore, E. C.; Zedeck, M. S.; Agrawal, K. C.; Sartorel. A.C. Inhibition of ribonucleoside diphosphate reductase by 1-formylisoquinoline thiosemicarbazone and related compounds. Biochemistry, 1970, 9(23), 4492-8.
242. Finch, R. A.; Liu, M. C.; Cory, A. H.; Cory, J. G.; Sartorelli, A. C. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP), an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv. Enzyme Regul., 1999, 39, 3-12.
243. Finch, R. A.; Liu, M. C.; Grill, S. P.; Rose, W. C.; Loomis, R.; Vasquez, K. M.; Cheng, Y. C.; Sartorelli, A. C. Triapine (3-aminopyridine-2-carboxaldehydethiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol., 2000, 59(8), 983-991.
244. Murren, J.; Modiano, M.; Clairmont, C.; Lambert, P.; Savaraj, N.; Doyle, T.; Sznol, M. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin. Cancer. Res., 2003, 9 (11), 4092-4100.
245. Yen, Y.; Margolin, K.; Doroshow, J.; Fishman, M.; Johnson, B.; Clairmont, C.; Sullivan, D.; Sznol, M. A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemoth. Pharm., 2004, 54(4), 331-342.
246. Wadler, S.; Makower, D.; Clairmont, C.; Lambert, P.; Fehn, K.; Sznol, M. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J. Clin. Oncol., 2004, 22(9), 1553-1563.
247. Knox, J. J.; Hotte, S. J.; Kollmannsberger, C.; Winquist, E.; Fisher, B.; Eisenhauer, E. A. Phase II study of triapinea (R) in patients with metastatic renal cell carcinoma: A trial of the national cancer institute of canada clinical trials group (NCIC IND.161). Invest. New Drugs, 2007, 25(5), 471-477.
248. Mackenzie, M. J.; Saltman, D.; Hirte, H.; Low, J.; Johnson, C.; Pond, G.; Moore, M. J. A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium. Invest. New Drugs, 2007, 25(6), 553-558.
249. Yuan, J.; Lovejoy, D. B.; Richardson, D. R. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood, 2004, 104(5), 1450-1458.
250. Whitnall, M.; Howard, J.; Ponka, P.; Richardson, D. R. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl. Acad. Sci. U.S.A. 2006, 103(40), 14901-14906.
251. Tian, J. Q.; Peehl, D. M.; Zheng, W. W.; Knox, S. J. Anti-tumor and radiosensitization activities of the iron chelator HDp44mT are mediated by effects on intracellular redox status. Cancer Lett., 2010, 298(2), 231-237.
252. Lovejoy, D. B.; Jansson, P. J.; Brunk, U. T.; Wong, J.; Ponka, P.; Richardson, D. R. Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. Cancer Res., 2011, 71(17), 5871-5880.
253. Knekt, P.; Reunanen, A.; Takkunen, H.; Aromaa, A.; Heliovaara, M.; Hakulinen, T. Body iron stores and risk of cancer. Int. J. Cancer, 1994, 56(3), 379-382.
254. Rao, V. A.; Klein, S. R.; Agama, K. K.; Toyoda, E.; Adachi, N.; Pommier, Y.; Shacter, E. B. The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase II alpha in breast cancer cells. Cancer Res., 2009, 69(3), 948-957.
255. Lovejoy, D. B.; Sharp, D. M.; Seebacher, N.; Obeidy, P.; Prichard, T.; Stefani, C.; Basha, M. T.; Sharpe, P. C.; Jansson, P. J.; Kalinowski, D. S.; Bernhardt, P. V.; Richardson, D. R. Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo. J. Med. Chem., 2012, 55(16), 7230-7244.
256. Kalinowski, D. S.; Yu, Y.; Sharpe, P. C.; Islam, M.; Liao, Y. T.; Lovejoy, D. B.; Kumar, N.; Bernhardt, P. V.; Richardson, D. R. Design, synthesis, and characterization of novel iron chelators: Structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents. J. Med. Chem., 2007, 50(15), 3716-3729.
257. Bernhardt, P. V.; Caldwell, L. M.; Chaston, T. B.; Chin, P.; Richardson, D. R. Cytotoxic iron chelators: characterization of the structure, solution chemistry and redox activity of ligands and iron complexes of the di-2-pyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues. J. Biol. Inorg. Chem., 2003, 8(8), 866-880.
258. Yu, Y.; Rahmanto, Y. S.; Richardson, D. R. Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy. Brit. J. Pharmacol., 2012, 165(1), 148-166.
259. Simonart, T.; Boelaert, J. R.; Andrei, G.; Van Den Oord, J. J.; Degraef, C.; Hermans, P.; Noel, J. C.; Van Vooren, J. P.; Heenen, M.; De Clercq, E.; Snoeck, R. Desferrioxamine enhances aids-associated Kaposi's sarcoma tumor development in a xenograft model. Int. J. Cancer, 2002, 100(2), 140-143.
260. Fu, D.; Richardson, D. R. Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1) by iron depletion. Blood, 2007, 110(2), 752-761.
261. Ponka, P.; Borova, J.; Neuwirt, J.; Fuchs, O.; Necas, E. Study of intracellular iron-metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating-agents. Biochim. Biophys. Acta, 1979, 586(2), 278-297.
262. Richardson, D. R.; Hefter, G. T.; May, P. M.; Webb, J.; Baker, E. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. III. Formation constants with calcium(II), magnesium(II) and zinc(II). Biol. Met., 1989, 2(3), 161-7.
263. Rama, R.; Octave, J. N.; Schneider, Y. J.; Sibille, J. C.; Limet, J. N.; Mareschal, J. C.; Trouet, A.; Crichton, R. R. Iron mobilization from cultured rat fibroblasts and hepatocytes - effect of various drugs. FEBS Lett., 1981, 127(2), 204-206.
264. Baker, E.; Vitolo, M. L.; Webb, J. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogs in hepatocytes in culture. Biochem. Pharmacol., 1985, 34(17), 3011-3017.
265. Cikrt, M.; Ponka, P.; Necas, E.; Neuwirt, J. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone. Brit. J. Haematol., 1980, 45(2), 275-283.
266. Buss, J. L.; Hermes-Lima, M.; Ponka, P. Pyridoxal isonicotinoyl hydrazone and its analogues. Adv. Exp. Med. Biol., 2002, 509, 205-229.
267. Chaston, T. B.; Richardson, D. R. Interactions of the pyridine-2-carboxaldehyde isonicotinoyl hydrazone class of chelators with iron and DNA: implications for toxicity in the treatment of iron overload disease. J. Biol. Inorg. Chem., 2003, 8(4), 427-438.
268. Darnell, G.; Richardson, D. R. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: The effect of the ligands on molecular targets involved in proliferation. Blood, 1999, 94(2), 781-792.
269. Sun, J.; Zhang, D.; Bae, D. H.; Sahni, S.; Jansson, P.; Zheng, Y.; Zhao, Q.; Yue, F.; Zheng, M.; Kovacevic, Z.; Richardson, D. R. Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors. Carcinogenesis, 2013, 34(9), 1943-54.
270. Park, G.; Lu, F. H.; Ye, N.; Brechbiel, M. W.; Torti, S. V.; Torti, F. M.; Planalp, R. P. Novel iron complexes and chelators based on cis,cis-1,3,5-triaminocyclohexane: iron-mediated ligand oxidation and biochemical properties. J. Biol. Inorg. Chem., 1998, 3(5), 449-457.
271. Planalp, R. P.; Przyborowska, A. M.; Park, G.; Ye, N.; Lu, F. H.; Rogers, R. D.; Broker, G. A.; Torti, S. V.; Brechbiel, M. W. Novel cytotoxic chelators that bind iron(II) selectively over zinc(II) under aqueous aerobic conditions. Biochem. Soc. Trans., 2002, 30(4), 758-62.
272. Zhao, R.; Planalp, R. P.; Ma, R.; Greene, B. T.; Jones, B. T.; Brechbiel, M. W.; Torti, F. M.; Torti, S. V. Role of zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Biochem. Pharmacol., 2004, 67(9), 1677-1688.
273. Abeysinghe, R. D.; Greene, B. T.; Haynes, R.; Willingham, M. C.; Turner, J. L.; Planalp, R. P.; Brechbiel, M. W.; Torti, F. M.; Torti, S. V. p53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Carcinogenesis, 2001, 22(10), 1607-1614.
274. Samuni, A. M.; Krishna, M. C.; DeGraff, W.; Russo, A.; Planalp, R. P.; Brechbiel, M. W.; Mitchell, J. B. Mechanisms underlying the cytotoxic effects of Tachpyr - a novel metal chelator. Biochim. Biophys. Acta Gen. Subjects, 2002, 1571(3), 211-218.
275. Greene, B. T.; Thorburn, J.; Willingham, M. C.; Thorburn, A.; Planalp, R. P.; Brechbiel, M. W.; Jennings-Gee, J.; Wilkinson, J.; Torti, F. M.; Torti, S. V. Activation of caspase pathways during iron chelator-mediated apoptosis. J. Biol. Chem., 2002, 277(28), 25568-25575.
276. Rakba, N.; Loyer, P.; Gilot, D.; Delcros, J. G.; Glaise, D.; Baret, P.; Pierre, J. L.; Brissot, P.; Lescoat, G. Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines. Carcinogenesis, 2000, 21(5), 943-951.
277. Biaso, F.; Baret, P.; Pierre, J. L.; Serratrice, G. Comparative studies on the iron chelators O-TRENSOX and TRENCAMS: selectivity of the complexation towards other biologically relevant metal ions and Al3+. J. Inorg. Biochem., 2002, 89(1-2), 123-130.
278. Rakba, N.; Aouad, F.; Henry, C.; Caris, C.; Morel, I.; Baret, P.; Pierre, J. L.; Brissot, P.; Ward, R. J.; Lescoat, G.; Crichton, R. R. Iron mobilisation and cellular protection by a new synthetic chelator O-Trensox. Biochem. Pharmacol., 1998, 55(11), 1797-1806.
279. Caris, C.; Baret, P.; Beguin, C.; Serratrice, G.; Pierre, J. L.; Laulhere, J. P. Metabolization of iron by plant cells using O-Trensox, a high-affinity abiotic iron-chelating agent. Biochem. J., 1995, 312, 879-885.
280. Gaboriau, F.; Laupen-Chassay, C.; Pasdeloup, N.; Pierre, J. L.; Brissot, P.; Lescoat, G. Modulation of cell proliferation and polyamine metabolism in rat liver cell cultures by the iron chelator O-trensox. Biometals, 2006, 19(6), 623-632.
281. Chapoutot, C.; Esslimani, M.; Joomaye, Z.; Ramos, J.; Perney, P.; Laurent, C.; Fabbro-Peray, P.; Larrey, D.; Domergue, J.; Blanc, F. Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis. Gut, 2000, 46(5), 711-714.
282. Ito, K.; Mitchell, D. G.; Gabata, T.; Hann, H. W. L.; Kim, P. N.; Fujita, T.; Awaya, H.; Honjo, K.; Matsunaga, N., Hepatocellular carcinoma: Association with increased iron deposition in the cirrhotic liver at MR imaging. Radiology, 1999, 212(1), 235-240.
283. Lescoat, G.; Leonce, S.; Pierre, A.; Gouffier, L.; Gaboriau, F. Antiproliferative and iron chelating efficiency of the new bis-8-hydroxyquinoline benzylamine chelator S1 in hepatocyte cultures. Chem. Biol. Interact., 2012, 195(2), 165-172.
284. Dexter, D. T. Parkinson's disease: Involvement of iron and oxidative stress. In Mechanisms and metal involvement in neurodegenerative diseases, Ward, R.; Crichton R.; Dexter D., Ed. RSC Publishing: Cambridge, 2013.